Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 17Cytarabine 11venetoclax 9fludarabine 9Mycophenolic Acid 8Busulfan 7fludarabine phosphate 6Whole-Body Irradiation 6ruxolitinib 5Tacrolimus 5Methotrexate 5Daunorubicin 5Cyclosporine 5Azacitidine 5ponatinib 4Vincristine 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Etoposide 4Dexamethasone 4blinatumomab 3asciminib 3Prednisone 3Mercaptopurine 3Inotuzumab Ozogamicin 3Doxorubicin 3revumenib 2quizartinib 2pegfilgrastim 2pegaspargase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × cedazuridine × 90 days × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡